REGENTIS BIOMATERIALS LTD.
No enriched coverage for $RGNT in the last 7 days.
No SEC Form 4 filings for $RGNT in the last 30 days.
See all $RGNT insider activity →Regentis Biomaterials (RGNT) is developing GelrinC, a treatment for knee cartilage repair. The product has early clinical support and European approval, with a U.S. trial ongoing. Researchers at Duke University and Mayo Clinic are also exploring cartilage regeneration. GelrinC aims to support natural cartilage repair, addressing a challenging medical issue.
Regentis Biomaterials (NYSE American:RGNT) reported H1 2026 results, highlighting progress in GelrinC U.S. trial with 43 patients treated and enrollment expected to complete by year-end. The company expanded European commercialization efforts and improved production yield by 400%. Regentis raised $6.5M in a private placement, with cash reserves of $9M as of June 30, 2026. H1 2026 net loss was $2.6M, an improvement from the same period in 2025.
REGENTIS BIOMATERIALS LTD. (RGNT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026 Expands European commercialization readiness,
Recent RGNT coverage spans earnings, financial news and market movers.
Positive trial progress may boost RGNT share price as investors anticipate regulatory approval.
The new earnings and capital raise provide fresh data on cash position and trial progress, potentially influencing short‑term price volatility.
Positive clinical progress and financing may support near‑term price appreciation.
Dilutive financing to extend GelrinC development through pivotal U.S. FDA study and PMA preparation.
Withdrawal of an F-1 tied to a planned public offering is a direct financing-plan reversal that can pressure sentiment and liquidity expectations.
AlphAI scores every news story that mentions RGNT with an AI model for sentiment and relevance, and aggregates insider trades from REGENTIS BIOMATERIALS LTD.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Regentis Biomaterials (RGNT) is developing GelrinC, a treatment for knee cartilage repair. The product has early clinical support and European approval, with a U.S. trial ongoing. Researchers at Duke University and Mayo Clinic are also exploring cartilage regeneration. GelrinC aims to support natural cartilage repair, addressing a challenging medical issue.
2 min readRegentis Biomaterials (NYSE American:RGNT) reported H1 2026 results, highlighting progress in GelrinC U.S. trial with 43 patients treated and enrollment expected to complete by year-end. The company expanded European commercialization efforts and improved production yield by 400%. Regentis raised $6.5M in a private placement, with cash reserves of $9M as of June 30, 2026. H1 2026 net loss was $2.6M, an improvement from the same period in 2025.
2 min readREGENTIS BIOMATERIALS LTD. (RGNT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026 Expands European commercialization readiness,
3 min readRegentis Biomaterials (NYSE American: RGNT) priced a $6.5 million private placement with accredited and institutional investors at $3.50 per ordinary share, plus accompanying warrants (or $3.4999 per pre-funded warrant). The company will issue 1,857,143 shares (or pre-funded warrants) and warrants to buy 1,857,143 shares. Pre-funded warrants are exercisable at $0.0001; ordinary warrants at $4.20 for five years. Net proceeds will fund its GelrinC pivotal trial, FDA pre-market approval preparation
4 min readRegentis Biomaterials (NYSE: RGNT) shares moved sharply after the company filed a Form 6-K with the SEC, saying it requested withdrawal of its Form F-1 registration statement and decided not to pursue the related public offering. The stock rose 506.45% to $9.40 intraday, then fell 9.15% to $8.54 in after-hours.
2 min readRegentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.
6 min readRegentis Biomaterials (NYSE: RGNT) has filed an F-1 registration statement to sell 3,333,334 Ordinary Shares at an assumed public offering price of $3.00 per share. The company is developing GelrinC, a regenerative medicine product for articular knee cartilage repair, which is currently undergoing a pivotal clinical trial. Regentis aims to use the net proceeds from this offering for further clinical development of GelrinC, research and development activities, operational readiness, and European market entry.
3 min read
